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INTRODUCTION
During embryogenesis, blood vessels are formed by twoprocesses, vasculogenesis and angiogenesis. Vasculogenesis is
the formation of new blood vessels involving de novo
differentiation of endothelial cells from mesoderm-derived
precursor cells (angioblasts) (Gonzalez-Crussi, 1971). In contrast,
angiogenesis, termed 'neovascularization', is the formation of new
blood vessels from a pre-existing vascular network, with continued
expansion of a vascular tree in response to an increase in tissue
mass (Risau, 1997; Carmeliet, 2005). Almost all tissues develop a
functional circulatory system by sprouting or non-sprouting
angiogenesis to form a primary capillary plexus. The metabolism
and survival of normal tissue depend on the adequate supply of
oxygen and nutrients from the vasculature. During adulthood,
however, cells of most blood vessels are quiescent, except for those
which respond to physiological processes such as wound healing,
tissue remodeling, and the female reproductive cycle and
pathological processes such as tumor expansion and metastasis
(Folkman and Shing, 1992; Folkman, 1995). However, dysregulated
and excessive vessel growth has a significant impact on health, and
contributes to various diseases. Insufficient vessel growth or
abnormal vessel regression causes stroke, Alzheimer's disease,
amyotrophic lateral sclerosis, hypertension, osteoporosis,
respiratory distress, and other disorders. In contrast, cancer,
rheumatoid arthritis, psoriasis, and diabetic retinopathy are the best-
known diseases resulting from excessive or abnormal angiogenesis
(Carmeliet, 2005).
The final event in endochondral ossification of bone growth and
development is the replacement of the avascular cartilage template
by highly vascularized bone tissue (Fig. 1). In this process,
chondrocytes become hypertrophic and then produce a calcified
cartilaginous extracellular matrix (ECM) and angiogenic
stimulators, thus providing a target for capillary invasion and
angiogenesis (Alini et al., 1996). The new vasculature supplies a
conduit for the recruitment of the cell types involved in cartilage
resorption and bone deposition, while providing the signals
necessary for normal morphogenesis (Harper and Klagsbrun, 1999).
Histological findings suggest that osteoblasts and osteoprogenitor
cells always develop concomitantly with endothelial cells in the
newly formed blood vessels at sites where new bone is formed
(Deckers et al., 2000). Capillary endothelial cells provide
microvasculature during bone remodeling (Erlebacher et al., 1995),
and this vascular invasion is a prerequisite for bone formation
(Guenther et al., 1986). Moreover, in the mandibular condyle, the
terminal ends of the penetrating capillaries closely follow the
outline of the previously eroded chondrocytic capsule, and the
process of erosion is closely related to and dependent on
osteoclastic activity (Durkin et al., 1973). Certainly, angiogenesis is
of critical importance for the growth and development of long
bones and the mandibular condyle, and these two biological events
share a common mediator.
Angiogenesis is thought to depend on a delicate balance between
endogenous stimulators and inhibitors (Polverini, 1995). Many
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molecules have been implicated as positive regulators of
angiogenesis, including members of the vascular endothelial
growth factor (VEGF) family, fibroblast growth factor (FGF),
transforming growth factor (TGF)-, TGF-, hepatocyte growth
factor (HGF), tumor necrosis factor (TNF)-, angiogenin,
interleukin (IL)-8, and the angiopoietins (Folkman and Shing,
1992; Yancopoulos et al., 2000). Among these pro-angiogenic
factors, VEGF, a homodimeric protein of 34 to 42 kDa, is a
fundamental and potent regulator of normal and abnormal
angiogenesis (Senger et al., 1993). It was first identified by
Ferrara and Henzel (1989) as an endothelial-specific growth
factor from bovine pituitary follicular cells, and is produced by
many types of cells, including fibroblasts, smooth-muscle cells,
hypertrophic chondrocytes, and osteoblasts (Gerber et al., 1999;
Ferrara and Gerber, 2001; Gerber and Ferrara, 2003).
Furthermore, VEGF-mediated angiogenesis is pivotal in growth
of the long bones and the mandibular condyle (Gerber et al.,
1999; Rabie and Hagg, 2002; Rabie et al., 2002a; Leung et al.,
2004). Recent studies have shown that VEGF may act as an
essential mediator during these processes and that it has multiple
functions, not only in bone angiogenesis, but also in different
aspects of bone development, including chondrocyte
differentiation, osteoblast differentiation, and osteoclast
recruitment (Zelzer et al., 2004; Zelzer and Olsen, 2005).
This review summarizes the ongoing efforts made in: (1)
characterizing VEGF family members, especially VEGF-A,
and their receptors; (2) investigating the regulatory system of
VEGF-A expression; (3) exploring the multiple roles of VEGF-
A in endochondral ossification of long bones, as well as in
mandibular condylar growth; and (4) developing therapeutic
applications for recombinant protein and gene therapy.
THE VEGF FAMILY AND ITS CHARACTERISTICS
VEGF is now understood to be one of a family of VEGFs that
includes VEGF, placenta growth factor (PLGF), and VEGF-B,
-C, -D, -E, and -F (Veikkola and Alitalo, 1999; Ferrara et al.,
2003; Roy et al., 2006). They all share a common structure of 8
characteristically spaced cysteine residues in a VEGF
homology domain.
VEGF-A
VEGF, generally referred to as VEGF-A, is a fundamental
mediator of physiologic and pathophysiologic angiogenesis. It
is also called vascular permeability factor (VPF) and is
produced by cultured vascular smooth-muscle cells (Tischer et
al., 1991). Structurally, VEGF-A is an antiparallel dimer that
has receptor-binding sites at each pole of the dimer. The
VEGF-A gene has been mapped to human chromosomes
6p21.3 (Vincenti et al., 1996), which can be alternatively
spliced to generate at least 6 distinct isoforms of 121, 145, 165,
189, and 206 amino acids (termed VEGF-A
121
, VEGF-A
145
,
VEGF-A
165
, VEGF-A
189
, and VEGF-A
206
, respectively); a
variant of VEGF-A
165
, namely, VEGF-A
165b
, has also been
identified (Tischer et al., 1991) (Fig. 2, Table 1). Murine
VEGF-As are shorter than the corresponding human isoforms
by 1 amino acid, and they are denoted VEGF-A
120
, VEGF-
A
144
, VEGF-A
164
, and VEGF-A
188
(Tamayose et al., 1996).
The VEGF-A isoforms have distinct biological activities, such
as differential interaction with heparan sulfate proteoglycans
(HSPGs) and neuropilin (NRP). The amino acids that are
encoded by exons 1-5 are conserved in all isoforms, but
alternative splicing can occur in exons 6 and 7 (Houck et al.,
1991).
VEGF-A
121
, the shortest splice form, is acidic and is more
freely diffusible. It lacks exons 6 and 7, which encode the
binding domains of HSPGs and NRPs. Consequently, VEGF-
A
121
does not bind either HSPGs or NRPs. The decreased
retention of VEGF-A
121
on the cell surface and in the ECM
renders this isoform highly diffusible, which acts as a
mitogenic and chemoattractant for endothelial cells during
angiogenesis and vasculogenesis (Houck et al., 1992).
VEGF-A
145
, an isoform lacking exons 6b and 7, appears in
an intermediary manner, since it is secreted, but a significant
segment remains bound to the cell surface and ECM (Ferrara
and Davis-Smyth, 1997). VEGF-A
145
binds to VEGFR-1,
VEGFR-2, HSPG, and NRP-2, but not to NRP-1 (Poltorak et
al., 1997; Gluzman-Poltorak et al., 2000). Binding to HSPG,
VEGF-A
145
was found to induce endothelial cell proliferation
and in vivo angiogenesis (Poltorak et al., 1997). However, the
Figure 1. Schematic representation of the role of VEGF in mandibular
condylar growth. The mandibular condyle is histologically distinguishable
as 5 different layers: the fibrus, proliferative, chondroblast, hypertrophic,
and erosive layers. Mesenchymal stem cells differentiate into
chondroblasts, which form the framework of the cartilage matrix. VEGF,
released from hypertrophic chondrocytes, induces endothelial cell
invasion, which in turn induces vascular channel formation in the terminal
layer of hypertrophic cartilage. The invading blood vessels bring
progenitor mesenchymal cells, which later differentiate into the osteoblasts
and chondroclasts/osteoclasts involved in endochondral ossification.
Some growth factors regulate VEGF expression and participate in
different stages of endochondral ossification.
Figure 2. VEGF-A isoforms. There are at least 6 different isoforms of
VEGF-A that arise by alternative exon splicing. VEGF165 is the
predominant molecular species among the isoforms.
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actual physiological roles of VEGF-A
145
's affinity to NRP-2
remain unclear.
VEGF-A
165
, lacking exons 6a and 6b, is physiologically the
most abundant isoform of VEGF-A (Tischer et al., 1991). It
binds to all of the receptors, including VEGFR-1, VEGFR-2,
HSPGs, NRP-1, and NRP-2. Moreover, the affinity to VEGFR-
1 is 10-fold higher than that to VEGFR-2 (Waltenberger et al.,
1994). VEGF-A
165
and VEGF-A
121
are highly expressed in
muscle, brain, kidney, eye, and chondrocytes (Gengrinovitch et
al., 1995). However, mice expressing only the VEGF-A
120
isoform (VEGF-A120/120) presented with delayed recruitment of
blood vessels into the perichondrium and delayed invasion of
vessels into the primary ossification center (Zelzer et al., 2002),
whereas VEGF-A164/164 mice showed normal vascular
development. In contrast, VEGF-A
121
was reported to have 10-
to 100-fold less endothelial cell mitogenic activity than VEGF-
A
165
, due to lack of a HSPG-binding basic region (Gitay-Goren
et al., 1996). Moreover, when chondrocytes are cultured in low
oxygen conditions, they secrete VEGF-A
165
. Both VEGF-A
165
and VEGF-A
121
might promote angiogenesis contributing to
long bone development, cause permeabilization of blood
vessels, induce proliferation of vascular endothelial cells, and
stimulate osteoclastogenesis for tooth eruption (Ng et al., 2001;
Wise and Yao, 2003; Cramer et al., 2004). The splice variant
VEGF-A
165b
contains the same quantity of amino acids as
VEGF-A
165
, except for 6 amino acids in the C-terminal region,
denoted exon 9 (Bates et al., 2002; Woolard et al., 2004). The
C-terminal is critical for mitogenic signaling; hence, the
differentiation in the VEGF-A
165b
variant is likely to affect its
biological activity (Cui et al., 2004; Woolard et al., 2004;
Byrne et al., 2005). Although VEGF-A
165b
can bind VEGFR-2,
its binding leads to neither phosphorylation of the receptor nor
activation of the downstream signal pathway. VEGF-A
165b
is
an endogenously inhibitory form of VEGF-A and reduces
VEGF-A-activated proliferation and migration of endothelial
cells (Cui et al., 2004; Woolard et al., 2004).
VEGF-A
189
and VEGF-A
206
contain all the exons. VEGF-
A
189
has an insertion of 24 amino acids that are highly enriched in
basic residues, and VEGF-A
206
has an additional insertion of 17
amino acids. These features mean that VEGF-A
189
and VEGF-
A
206
are not secreted from cell surfaces, but are tightly bound to
HSPGs and NRP, allowing for the sequestration of VEGF-A
189
and VEGF-A
206
in the ECM and on cell surfaces (Houck et al.,
1992; Park et al., 2003). VEGF-A
189
is usually present in low
amounts, and VEGF-A
206
expression is restricted to embryonic
tissues (Ferrara and Davis-Smyth, 1997). Hence, they are less
active than other isoforms secreted in vivo, such as VEGF-A
121
,
VEGF-A
145
, and VEGF-A
165
. Protease cleavage of matrix-bound
VEGF-A
189
allows for the release of an active, freely diffusible
110-amino-acid fragment (Lee et al., 2005). A recent study
demonstrated that VEGF-A
189
could promote endothelial cell
proliferation and migration in vitro, and angiogenesis in the
Matrigel plug assay in vivo (Herve et al., 2005). However, VEGF-
A188/188 mice showed dwarfism, impaired development of growth
plates and secondary ossification centers, and knee joint
dysplasia. This phenotype was at least partly due to defective
vascularization surrounding the epiphysis, leading to ectopically
increased hypoxia and massive chondrocyte apoptosis in the
interior of the epiphyseal cartilage. In addition, an in vitro study
showed that the VEGF-A
188
isoform alone is also insufficient to
regulate chondrocyte proliferation and survival responses to
hypoxia (Maes et al., 2004).
PLGF
The first member of the VEGF family to be discovered, PLGF,
shares 53% identity with the platelet-derived growth factor
(PDGF)-like region of VEGF (Nissen et al., 1998). The human
PLGF gene has been mapped to chromosome 14q24 (Mattei et
al., 1996). PLGF is anticipated to have 149 amino acids and is
encoded by 7 exons that span 800 kb (Roy et al., 2006). By
alternative splicing, 4 forms of PLGF protein are generated:
PLGF-1, PLGF-2, PLGF-3, and PLGF-4 (Maglione et al., 2000).
Only PLGF-2 is capable of binding heparin (Hauser and Weich,
1993). Overexpression of PLGF-2 in perivascular tissue raises
VEGF-A
165
and VEGF-A
121
levels and produces significant
angiogenesis (Roy et al., 2006). PLGF has a powerful
chemotactic effect on monocytes, since injection of PLGF
protein and adenovirus-mediated PLGF gene transfer increases
macrophage accumulation (Roy et al., 2005). Furthermore,
PLGF deficiency impairs proliferation and differentiation of
osteochondroprogenitors during bone repair (Maes et al., 2006).
VEGF-B
VEGF-B, which is also called VEGF-related factor (VRF),
encodes 188 amino acids, consists of 8 exons and 6 introns, and
is located on chromosome 11q13 (Paavonen et al., 1996).
VEGF-B transcripts can be alternatively spliced into two
different variants encoding proteins VEGF-B
167
and VEGF-
B
186
(Li et al., 2001). The promoter region of VEGF-B is
Table 1. Properties of the VEGF-A Isoforms
Isoforms Structure Binding Ability Functions References
VEGF-A121 Lacks exons 6 &7 VEGFR-1,-2 * EC proliferation, migration, Houck et al., 1992; Wise and Yao, 2003
osteoclastogenesis
VEGF-A145 Lacks exons 6b &7 VEGFR-1,-2, HSPG, NRP-2  EC proliferation Poltorak et al., 1997
VEGF-A165 Lacks exons 6a & 6b VEGFR-1,-2, HSPG, NRP-1,-2  EC proliferation, permeabil- Wise and Yao, 2003; Cramer et al., 2004
ization, osteoclastogenesis
VEGF-A165b Lacks exons 6a & 6b VEGFR-1,-2, HSPG, NRP-1,-2  EC proliferation, migration Cui et al., 2004
VEGF-A189 Contains all the exons HSPG, NRP-1,-2  EC proliferation, migration Herve et al., 2005
VEGF-A206 Contains all the exons HSPG, NRP-1,-2 ND Ferrara and Davis-Smyth, 1997
*  induced,  inhibited. EC, endothelial cells; ND, not determined.
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similar to that of VEGF-A, in that both promoters are
associated with a CpG island and contain transcription-factor-
binding sites for Sp1 and AP-2 (Silins et al., 1997). However,
the VEGF-B promoter includes Egr-1 sites, not hypoxia-
inducible factor-1 and AP-1 sites. Consequently, stimuli such
as hypoxia, which can regulate VEGF-A expression, appear to
have no effect on the expression of VEGF-B (Enholm et al.,
1997; Roy et al., 2006). VEGF-B is highly abundant in the
heart, skeletal muscle, and pancreas and is required in
vascularization of skeletal muscle (Enholm et al., 1997).
Silvestre et al. (2003) demonstrated that VEGF-B, partly
through its receptor VEGFR-1, induces angiogenesis associated
with an activation of Akt and eNOS-related pathways.
VEGF-C
VEGF-C, which is also referred to as VEGF-related protein
(VRP), is located on chromosome 4q34 (Paavonen et al.,
1996). The VEGF-C gene contains more than 40 kb of genomic
DNA and consists of 7 exons (Roy et al., 2006). VEGF-C is a
secreted protein that consists of 399 amino acids and was
identified as a ligand for the tyrosine kinase receptor VEGFR-
3, which is associated with the lymphatic vasculature
(Karkkainen et al., 2004). Structurally, VEGF-C shares
approximately 30% sequence homology with the central core
of VEGF-A. In vivo, VEGF-C can stimulate angiogenesis in a
rabbit ischemic hind-limb model, rabbit cornea assay, and early
chick chorio-allantoic membrane. In vitro, VEGF-C can
stimulate endothelial cell proliferation and migration, but it is
less potent than VEGF-A. Gene transfer of VEGF-C produced
moderate angiogenesis in rabbit skeletal as well as perivascular
tissue (Bhardwaj et al., 2003). VEGF-C is overexpressed in
rheumatoid arthritis (RA) synovial tissues, when compared
with osteoarthritis (OA) or normal synovial tissues (Wauke et
al., 2002). In addition, tumor necrosis factor (TNF)- has been
recently identified to induce VEGF-C expression significantly
in rheumatoid synoviocytes in a dose-dependent manner. It
suggests that VEGF-C may be
indispensable for the pathogenesis
of RA through contributing to local
lymphangio genesis and tumor
angiogenesis (Cha et al., 2007).
VEGF-D
VEGF-D, also called c-fos-induced
growth factor (FIGF), can activate
the receptors VEGFR-2 and
VEGFR-3 in humans, but only
VEGFR-3 in mice (Baldwin et al.,
2001). It is expressed in many adult
tissues, including the limb buds,
teeth, liver, and heart as well as the
lung and kidney mesenchyme and
periosteum of the vertebral column
(Avantaggiato et al., 1998). The
human VEGF-D gene is 2.0 kb in
size and is located on chromosome
Xp22.31 (Yamada et al., 1997).
VEGF-D is mitogenic for
endothelial cells in vitro (Bhardwaj
et al., 2003), angiogenic in vivo and
in vitro (Marconcini et al., 1999),
and lymphangiogenic in tumors
(Miyata et al., 2006). Compared with other human VEGFs,
VEGF-D is thought to be the most potent angiogenic and
lymphangiogenic factor when delivered into rabbit hindlimb
skeletal muscle through adenoviral vector-mediated gene
transfer (Rissanen et al., 2003).
VEGF-E
VEGF-E was first identified in the genome of NZ-7, NZ-2, and
D1701 strains of the Orf virus, a parapoxvirus that infects goats,
sheep, and occasionally humans (Ferrara and Davis-Smyth, 1997;
Ogawa et al., 1998). VEGF-E exclusively binds to VEGFR-1
with high affinity, similar to VEGF-A
165
, resulting in receptor
autophosphorylation and a biphasic rise in the intracellular
concentration of free calcium ions (Meyer et al., 1999). Although
VEGF-E does not bear a heparin-binding basic region,
structurally similar to VEGF-A
121
, its biological activities for
endothelial cell growth and vascular permeability are almost
equal to those of the potent angiogenesis and vascular
permeability factor, VEGF-A
165
(Ogawa et al., 1998). This VEGF
homolog is a potent angiogenesis stimulator and can induce the
proliferation, migration, sprouting, and mitotic activity of vascular
endothelial cells. More recently, Inoue et al. (2006) reported that
plasmid-mediated VEGF-E/PLGF chimera gene therapy
significantly promoted angiogenesis in a rat model of hindlimb
ischemia without stimulating inflammatory cell infiltration.
VEGF-F
The seventh member of the VEGF family, VEGF-F, was
recently identified from snake (viper) venom (Suto et al.,
2005). VEGF-F consists of 2 VEGF-related proteins,
designated vammin (110 residues) and VR-1 (109 residues),
both of which have a 50% primary structural identity with
VEGF-A
165
and bind selectively to VEGFR-2 (Suto et al.,
2005). VEGF-F contains a short C-terminal heparin-binding
region; the C-terminus of VEGF-F specifically blocks VEGF-
A
165
activity both in vitro and in vivo (Yamazaki et al., 2005).
Figure 3. Schematic representation of the VEGF receptors and their ligands. The tyrosine kinase
receptors (VEGFR-1/Flt-1, VEGFR-2/KDR/Flk-1, VEGFR-3/Flt-4) are organized into 7 extracellular
immunoglobulin (Ig)-like domains. VEGF binding has been localized to the second and third Ig-like
domains. The fourth Ig-like domains are thought to interact directly with each other in a ligand-induced
receptor dimer. In VEGFR-3, the fifth Ig domain is replaced by a disulfide bridge. The extracellular
domain is followed by a single transmembrane region, a split tyrosine-kinase domain. The interaction
of VEGFR-1, -2 with either NRP-1, -2, or HSPG may facilitate the binding of VEGF to its receptor.
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VEGF RECEPTORS
The main receptors involved in VEGF signal transduction are
the PDGF receptor subfamily of receptor tyrosine kinases
(RTKs)—namely, VEGFR-1, VEGFR-2, VEGFR-3—as well
as co-receptors, such as NRP-1 and -2 and HSPGs (Ferrara et
al., 2003) (Fig. 3). More than one type of VEGF receptor
contributes to the biological responses to VEGF, thereby
ensuring balanced signaling.
VEGFR-1
VEGFR-1, or fms-like tyrosine kinase receptor 1 (flt-1), is a
180-kDa transmembrane protein that is considered to be
integral to vascular maintenance and the recruitment of
endothelial precursor cells during vasculogenesis (Shibuya,
2006). It binds to all the isoforms of VEGF-A, VEGF-B, and
PLGF, and transduces the distinct biological responses (Park et
al., 1994; Olofsson et al., 1998). Autiero et al. (2003)
suggested that the mechanism underlying the different
responses of VEGF and PLGF might be the induction of
different phosphorylation patterns in VEGFR-1. Another
important feature of VEGFR-1 is that the soluble VEGFR-1
can function as a natural VEGF-A inhibitor (a decoy receptor).
These unique characteristics of VEGFR1 suggest that it acts as
both a negative regulator, via its ligand-binding domain
mediated by VEGFR-2, and a positive regulator, via its tyrosine
kinase (Gille et al., 2001). Moreover, VEGFR1 might be
influenced through interaction with VEGFR-2. VEGFR-1-/-
embryonic stem cells resulted in the increased differentiation of
endothelial cells, but assembly of these cells into abnormal
vascular channels mediated by the increased phosphorylation of
VEGFR-2 (Fong et al., 1995; Roberts et al., 2004). In contrast,
VEGFR-2-mediated proliferation of endothelial cells can be
suppressed by VEGFR-1, and this effect is dependent on PI3K
(Zeng et al., 2001). More recently, mice that were deficient in
flt-1 signaling (op/opFlt1TK-/-) were shown to have very
depleted numbers of osteoclasts and osteoblasts, and,
consequently, also a deficiency in bone marrow cavity
formation. The fibrous tissue gradually filled in the narrow
bone marrow cavity, resulting in severe marrow hypoplasia
(Niida et al., 2005). These findings suggested that VEGFR-1
signaling is critical for osteoblast activity during bone
formation through participation in osteoclastogenesis, as well
as in the maintenance of a bone marrow hematopoiesis-
supportive microenvironment.
VEGFR-2
VEGFR-2, or kinase insert domain-containing receptor
(KDR)/fetal liver kinase 1 (flk-1), is a 230-kDa glycoprotein
that is thought to mediate almost all of the observed endothelial
cell responses to VEGF (Neufeld et al., 1999). It binds to all
the isoforms of VEGF-A, VEGF-C, VEGF-D, and VEGF-F,
but not VEGF-B
167
and PLGF (Ferrara and Davis-Smyth,
1997). VEGFR-2 is predominantly located on the surfaces of
endothelial cells and is thought to initiate intracellular signal
transduction, which is associated with the integrin-dependent
migration of endothelial cells, since it can form a complex with
integrin V
3
and the induction of endothelial cell
proliferation, migration, and in vivo angiogenesis (Hutchings et
al., 2003). It has been reported that VEGFR-2-mediated cell
migration induced by VEGF-A
165
, but not by VEGF-A
121
, is
strongly enhanced in the presence of NRP-1 receptors (Shraga-
Heled et al., 2007). VEGFR-2 knockout mice showed severely
impaired vasculogenesis and hematopoiesis in the embryo,
leading to embryonic death (Shalaby et al., 1995). Moreover,
expression of VEGFR-2 occurs in a differentiation-dependent
manner and declines post-natally (Millauer et al., 1993). In
contrast, the binding of VEGF to VEGFR-1 does not seem to
result in the induction of cell proliferation, and it is believed
that its role is mainly inhibitory (Shraga-Heled et al., 2007).
VEGFR-3
VEGFR-3 or flt-4, a 170-kDa glycosylated protein, is a
receptor for VEGF-C and VEGF-D, but not for VEGF-A. It is
required for the development of blood as well as lymphatic
vessels and is thought to have a general function in blood
vascularization during early development (Lohela et al., 2003);
later, its role becomes restricted mostly to the development of
the lymphatic vascular system (Dayoub et al., 2003).
Furthermore, expression of VEGFR-3 has been reported to be
higher in human osteoarthritic chondrocytes than in persons
without arthritis (Shakibaei et al., 2003).
NRPs
NRPs were recently identified to be VEGF co-receptors and
belong to a family of non-tyrosine kinase transmembrane
receptors that have a small cytoplasmic domain and multiple
extracellular domains (Soker et al., 1998). NRP-1 lacks an
intracellular tyrosine kinase domain and therefore must act in
conjunction with other receptors to mediate VEGF signaling. It
can associate with both VEGFR-1 and VEGFR-2 by
specifically binding VEGF-A
165
and PLGF, VEGF-B, and
VEGF-E, but not VEGF-A
121
(Zelzer et al., 2001). NRP-2 also
lacks a cytoplasmic signaling domain and can bind to VEGF-
A
165
, VEGF-A
145
, and PLGF and can interact with VEGFR-1
(Gluzman-Poltorak et al., 2000, 2001). NRPs act as active
mediators in immune responses, neuronal development, and
angiogenesis (Klagsbrun et al., 2002). Deletion of the NRP-2
gene impairs formation of small lymphatic vessels, suggesting
that NRP-2 may act as a co-receptor for VEGFR-3 (Yuan et al.,
2002). Both NRP-1 and NRP-2 can enhance VEGF-A
121
-
induced phosphorylation of VEGFR-2 and VEGF-A
121
-induced
proliferation of endothelial cells. The enhancement of VEGF-
A121 activity by NRP-1 has been reported to be accompanied
by a significant increase in the binding affinity of VEGFR-2 to
VEGF-A
121
and was not associated with the formation of new
VEGFR-2/NRP-1 complexes (Shraga-Heled et al., 2007).
NRP-1 expression in cultured MC3T3-E1 osteoblasts was
down-regulated in a differentiation-dependent manner and
bound to VEGF-A
165
(Deckers et al., 2000). Consistent with
the in vitro studies, NRP1 is expressed in vivo by osteoblasts,
but not osteocytes, in the metaphysis and trabeculae of growing
mouse bones and embryonic chick bones (Harper et al., 2001).
The overexpression of NRP-1 showed extra digits, suggesting
that limb morphogenesis is very sensitive to exogenous
neuropilin expression (Kitsukawa et al., 1995). In addition, the
binding of semaphorin-3A (an axonal chemorepellent) to NRP-
1 may compete with VEGF-A
165
for an overlapping binding
site on NRP-1, and may inhibit the migration of endothelial
cells and the outgrowth of capillary tubes from rat aortic
segments (Narazaki and Tosato, 2006). Thus, NRP-1 appears to
be a novel regulator of osteoblast activity in development of the
skeletal system, and semaphorin-3A might affect its affinity to
VEGF-A
165
. However, the contribution of NRP-2 to bone
development is still unclear.
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HSPGs
HSPGs are transmembrane, glycosylphosphatidylinositol-
anchored or secreted proteins that contain covalently linked
heparan sulfate chains that modulate the activity of a large
number of secreted signaling molecules. HSPGs might regulate
the binding of VEGF-A
165
to its receptors via an accessory
low-affinity binding site; in this way, HSPGs promote VEGF-
A
165
signaling in transit from the surface of an adjacent cell
(Houck et al., 1992; Selleck, 2006). Such ligand-receptor
interactions stimulate VEGFR-2 turnover and cause a marked
increase in duration and amplitude of the VEGFR signal
(Jakobsson et al., 2006; Selleck, 2006). HSPGs also have
profound effects on the bioactivity of VEGF-A
165
, but not
VEGF-A
121
: The high-affinity binding to VEGF-A
165
affects its
diffusion, half-life, and interaction through VEGFR-2 (Larrivee
and Karsan, 2000; Stringer, 2006). HSPGs are considered to be
both important co-receptors and important regulators of VEGF-
A gradients. Exogenous heparin is known to inhibit both
binding ability between VEGFR-2 and VEGF-A
165
and
autophosphorylation of VEGFR-2 induced by VEGF-A
165
, but
it has no effect on the interaction of VEGFR-2 with VEGF-
A
121
(Tessler et al., 1994). In contrast, exogenous heparin
significantly inhibits the affinity for VEGFR-1 with both
VEGF-A
165
- and VEGF-A
121
(Cohen et al., 1995). These
observations suggest that the C-terminal region of VEGF-A
165
is important in the interaction of cell-associated VEGFR-2,
while heparin affects the activity role of VEGFR-1
independently of the heparin-binding ability of the ligands
(Yamazaki and Morita, 2006).
REGULATION OF VEGF-A GENE EXPRESSION
Several mechanisms have been demonstrated to be involved in
the regulation of VEGF expression, including hypoxia and
several growth factors and hormones. An overview of the
regulation factors appears in Table 2, and these will be
discussed in the following sections.
Hypoxia
Oxygen plays a critical role, both in vitro and in vivo, in the
regulation of VEGF-A expression. Hypoxic induction of
VEGF-A appears to be a ubiquitous response, in which the 28-
base consensus sequence in the 5
VEGF promoter is augmented by a
3 enhancer (Levy et al., 1995).
Under hypoxic conditions, hypoxia-
inducible factor-1 (HIF-1) binds
to the 5 consensus sequence in the
VEGF-A promoter, termed the
'hypoxia responsive element', which
in turn increases VEGF-A
transcription (Madan and Curtin,
1993). Hypoxia-induced VEGF-A
up-regulation is controlled at both
the transcriptional and post-
transcriptional levels (Dibbens et al.,
1999). A study of human osteoblast-
like MG63 cells revealed that
transcriptional regulation of VEGF-
A mRNA expression under hypoxic
conditions is mediated through
increased levels of the basic-helix-
loop-helix transcription factor Hif-2, but not Hif-1 (Akeno et
al., 2001). The induction of VEGF-A by Hif-2 is likely to
represent a physiologically relevant response to hypoxia in
osteoblasts. However, HIF-1-null chondrocytes were unable
to maintain ATP levels in hypoxic microenvironments,
indicating a fundamental requirement for HIF-1 in the
regulation of chondrocyte metabolism, and hence
vascularization during long-bone development (Pfander et al.,
2003; Cramer et al., 2004).
Cbfa1
Cbfa1 (core-binding factor a1, also called runx2, Osf2, or
AML3), a homolog of the Drosophila Runt protein, is a
transcription factor that is required for endochondral and
intramembranous bone formation. It is expressed in osteoblasts,
pre-chondrogenic mesenchymal condensations, and
hypertrophic chondrocytes, where it serves as the earliest
transcriptional regulator of osteoblast differentiation (Rabie et
al., 2004; Tang and Rabie, 2005). Cbfa1 is sufficient to induce
premature and ectopic chondrocyte hypertrophy (Rabie et al.,
2004). In Cbfa1-deficient mice, VEGF-A cannot be up-
regulated, chondrocyte differentiation to hypertrophy is
impaired, and cartilage angiogenesis does not occur. These
findings demonstrate that Cbfa1 is an essential factor for
mediating VEGF-A functions during endochondral ossification
(Zelzer et al., 2001). Whether Cbfa1 acts as a direct
transcriptional regulator of the VEGF-A gene is unclear.
However, the VEGF-A promoter contains Cbfa1 binding sites,
and over-expression of Cbfa1 in cultured fibroblasts increases
both mRNA and protein expression levels of VEGF (Zelzer et
al., 2001).
BMPs
Bone morphogenetic proteins (BMP) are multi-functional
growth factors that belong to the TGF- superfamily. The
addition of BMP-2, -4, and -6 to the murine osteoblast-like cell
line KS483 led to an augmentation of calcium deposition and
VEGF-A production in a dose-dependent manner (Deckers et
al., 2000). Osteogenic protein-1 (OP-1 or BMP-7) increased the
steady-state level of VEGF-A mRNA by about three-fold in an
OP-1 concentration- and time-dependent manner in primary
cultures of fetal rat calvaria cells. The increase in VEGF-A
Table 2. Regulation of VEGF Gene Expression
Factors Functions Role in VEGF Expression References
HIF1a Hypoxic mediator and regulates up-regulation Dibbens et al., 1999
chondrocyte metabolism
Cbfa1 Regulates osteoblast differentiation and Zelzer et al., 2001
chondrocyte maturation up-regulation
BMPs Regulate chondrocyte and osteoblast up-regulation Yeh and Lee, 1999
differentiation
TGF-1 Regulates osteoblast differentiation up-regulation Spector et al., 2000
CTGF Regulates chondrocyte proliferation up-regulation Ivkovic et al., 2003
and ECM production
MMP-9 Regulates ECM degradation up-regulation Vu et al., 1998
TNF- Regulates osteoclast recruitment up-regulation Wise and Yao, 2003
and differentiation
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mRNA level depended on transcription and was sensitive to cell
replication (Yeh and Lee, 1999). The mRNA levels for VEGFR-
1 and VEGFR-2 in the fetal rat calvaria cells were low but
detectable by RT-PCR, and were not changed by OP-1 (Yeh and
Lee, 1999). Kakudo et al. (2006) investigated whether
recombinant human BMP-2 could cause undifferentiated
mesenchymal cells to differentiate into chondrocytes and
osteoblasts, which then expressed VEGF, thereby creating an
advantageous environment for vascularization in bony tissue. In
addition to increased VEGF-A expression, BMP-2 is able to up-
regulate VEGF-B and VEGF-C expression and synthesis, as
well as increase VEGFR-2 levels (Bluteau et al., 2007).
TGF-1
At least part of the osteogenic activity of TGF-1 may be
attributed to the production of VEGF-A (Chang et al., 2003).
The addition of TGF-1 to MC3T3-E1 cells induced VEGF-A
mRNA production, and this induced expression was
superinduced by cycloheximide and blocked by actinomycin D
and Ro 31-8220, a protein kinase C (PKC) inhibitor. Curcumin,
an inhibitor for transcription factor AP-1, also blocked the
induction (Spector et al., 2000). Moreover, phorbolmyristate
acetate (PMA), a PKC activator, can enhance VEGF expression
in cultured dental follicle cells (Wise and Yao, 2003). Further
research has shown that both p44/p42 MAP kinase and p38
MAP kinase contribute to TGF--stimulated VEGF-A
synthesis in osteoblasts, which suggests a positive feedback
loop for osteoblast differentiation (Tokuda et al., 2003a).
CTGF
Connective tissue growth factor (CTGF) is a crucial regulator
of cartilage ECM (Perbal, 2004). Ctgf deficiency in Ctgf(-/-)
mice leads to skeletal dysmorphisms, as a result of impaired
endochondral ossification (Ivkovic et al., 2003). These defects
are linked to decreased expression of VEGF-A mRNA and
protein levels in the expanded hypertrophic zone in newborn
Ctgf mutants. Thus, VEGF-A is probably a target of CTGF
action in hypertrophic cartilage (Ivkovic et al., 2003).
Moreover, this decrease is not the result of reduced Cbfa1
expression, suggesting that CTGF is either downstream of, or
acts in parallel with, Cbfa1 in regulating VEGF-A expression
(Ivkovic et al., 2003). VEGF-A
165
-induced angiogenesis was
reported to be inhibited selectively and strongly by complexing
with CTGF. This complex formation interrupts the binding of
VEGF-A
165
to VEGFR-2 (Inoki et al., 2002).
MMP9
Reduced expression of the osteoclastic protease MMP9 affects
angiogenesis-inducing activity in growth plates (Vu et al., 1998),
and MMP9-null growth plates share several characteristics with
mouse growth plates in which VEGF-A activities have been
blocked, such as expansion of the hypertrophic layer and
reduction in both vascularization and ossification (Vu et al.,
1998). Hence, it has been suggested that MMP9 regulates
vascular invasion by releasing the VEGF-A that is bound to the
hypertrophic cartilage matrix. Once released, VEGF-A can bind
to its receptors on endothelial cells, osteoclasts, and osteoblasts,
and, in so doing, can stimulate their migration and activity at the
fracture site (Nakagawa et al., 2000).
TNF-
TNF-  is a pro-inflammatory cytokine that enhances VEGF-A
expression in follicle cells and periodontal ligament cells
(Oyama et al., 2000; Wise and Yao, 2003). The enhanced
expression of VEGF-A in the dental follicle cells by TNF- is
considerable and could be the main avenue by which TNF-
expression leads to the recruitment and differentiation of
osteoclasts (Wise and Yao, 2003).
Hormones
It is widely recognized that the role of thyroid hormone in bone
metabolism is mainly ascribed to the regulation of osteoblast
activities. Triiodothyronine (T
3
) alone could stimulate VEGF-A
release in MC3T3-E1 cells, so it is likely that thyroid hormone
stimulates bone metabolism partially via the up-regulation of
VEGF-A release (Tokuda et al., 2003b). In human osteoblast-
like cells, a steady expression of VEGF-A is induced by 1,25-
dihydroxyvitamin D
3
[1,25-(OH)
2
D
3
] (Wang et al., 1996).
Furthermore, when alkaline phosphatase(ALP)-positive human
osteoblast-like cells are co-cultured with ALP-negative human
umbilical vein endothelial cells, the addition of 1,25-(OH)
2
D
3
stimulates ALP activity in the osteoblast-like cells, and
increases the expression of VEGF mRNA, followed by
increased secretion of VEGF-A (Petit et al., 1997). More
recently, ED-71, a novel vitamin D[1,25-(OH)
2
D
3
] analog, has
been demonstrated to improve angiogenesis within the bone
marrow cavity through the increased expression of VEGF-A
120
(Okuda et al., 2006).
ANGIOGENESIS AND 
ENDOCHONDRAL OSSIFICATION
VEGF-A is predominantly produced in tissues that acquire new
capillary networks (Shweiki et al., 1993), and the importance
of VEGF-A during angiogenesis has been demonstrated in gene
knockout studies. Homozygous Vegfa knockout mice die at
embryonic days E8-E9, and mice lacking a single Vegfa allele
die at days E11-E12, due to deficient endothelial cell
development and lack of blood vessels (Carmeliet et al., 1996;
Tammela et al., 2005). Moreover, inducible deletion of VEGF-
A in neonatal mice results in stunted growth and increased
apoptosis of endothelial cells (Gerber et al., 1999). The
knockout of one allele of VEGFR-2 in mice also resulted in
lack of normal blood vessel development and embryonic
lethality (Shalaby et al., 1995). The failure of vasculogenesis
leads to growth retardation, developmental anomalies, and,
ultimately, embryonic lethality (Carmeliet et al., 1996). Using a
VEGF-A120/120 mouse model created by Cre-loxP-mediated
removal of VEGF-A exons 6 and 7, researchers showed that
VEGF-A
164
and/or VEGF-A
188
is important in both mediating
vascularization and ensuring the normal differentiation of
progenitors into hypertrophic chondrocytes, osteoblasts,
endothelial cells, and osteoclasts (Maes et al., 2002, 2004).
Hence, VEGF-A is not only essential for normal
angiogenesis, but it is also involved in endochondral
ossification (Midy and Plouet, 1994; Gerber et al., 1999; Rabie
et al., 2002a; Aldridge et al., 2005) (Fig. 1). Cells in the upper
zone of the hypertrophic cartilage, especially in the mandibular
condyle, secrete VEGF-A, which then regulates the invasion of
new blood vessels from the perichondrium and influences the
removal of the cartilage matrix (Rabie and Hagg, 2002; Rabie
et al., 2002a). The invading blood vessels bring progenitor
mesenchymal cells to the mineralization front, and the cells
later differentiate into osteoblasts and chondroclasts/osteoclasts
involved in endochondral ossification (Rabie and Hagg, 2002;
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Leung et al., 2004). In 24-day-old mice, inactivation of VEGF-
A through the systemic administration of a soluble VEGF-A
receptor protein, Flt-(1-3)-IgG, suppresses blood vessel
invasion, impairs trabecular bone formation, and expands the
hypertrophic zone in the growth plate (Gerber et al., 1999). The
chondrocyte-specific inactivation of VEGF-A results in
aberrant endochondral bone formation, lack of normal blood
vessel development, and embryonic lethality in transgenic mice
(Haigh et al., 2000). Therefore, VEGF-A seems to play a key
role in the highly regulated process of endochondral
ossification, which depends on the interplay of chondrocytes,
osteoblasts, and osteoclasts/chondroclasts (Fig. 4).
VEGF-A Regulates Chondrocyte Activity
In rats, VEGF-A protein is expressed at low levels in maturing
chondrocytes; however, it is expressed at high levels in
hypertrophic chondrocytes and in mineralized regions of the
cartilage of the growth plate in neonatal wild-type and in the
mandibular condyle of growing and adult rats (Carlevaro et al.,
2000; Rabie and Hagg, 2002; Henriksen et al., 2003; Leung et
al., 2004; Xiong et al., 2005). With the C28/12 cell line
(immortalized chondrocytes), the proliferation of chondrocytes
can be induced by the addition of VEGF in a dose-dependent
manner (Pufe et al., 2004). In addition, VEGF-A, VEGF-B,
VEGF-C, and VEGF-D were detectable and up-regulated at the
mRNA and protein levels during chondrogenic differentiation
of primary chondrocytes in the ATDC5 chondrogenic cell line
(Bluteau et al., 2007). More recently, some studies have
demonstrated that VEGF-A secretion by hypertrophic
chondrocytes is not only a paracrine process that attracts and
stimulates proliferation of endothelial cells, but is also an
autocrine process that is needed for chondrocyte survival (Maes
et al., 2004; Zelzer et al., 2004; Zelzer and Olsen, 2005).
Moreover, culture of chondrocytes under hypoxic conditions
up-regulates VEGF-A expression via H1F-1a (Pfander et al.,
2003). Thus, VEGF-A signaling appears to occur downstream
of HIF-la in the chondrocyte survival pathway. Recently,
VEGFR-2 was revealed to co-localize with VEGF-A in the
hypertrophic layer, whereas VEGFR-1 and VEGFR-3 were
rarely detectable (Carlevaro et al., 2000). Similarly, NRP-1 and
NRP-2 expression by chondrocytes may be an
autocrine/paracrine process that maintains chondrocyte survival
and controls cell differentiation and proliferation (Maes et al.,
2004; Zelzer et al., 2004; Zelzer and Olsen, 2005; Bluteau et
al., 2007).
VEGF-A Regulates Chondroclast/Osteoclast Activity
It seems that VEGF-A is involved in controlling endothelial
cell activities, as well as in osteoclastic differentiation,
migration, and activity (Zelzer and Olsen, 2005). In addition,
cartilage and bone resorption by chondroclasts and osteoclasts
regulates vascular invasion and relies on degradation of the
cartilaginous matrix, which occurs mainly via the release of
VEGF-A (Rabie et al., 2002a,b). In fact, osteoclasts express
VEGF receptor 1, which can bind VEGF-A to induce osteoclast
recruitment and bone-resorption activity (Niida et al., 2005). A
single injection of recombinant human VEGF-A (rhVEGF-A)
into osteopetrotic op/op mice (lack of CSF-1) induced
osteoclast recruitment and survival, while stimulating
osteoclastic bone resorption (Niida et al., 1999). In contrast, the
inhibition of VEGF-A resulted in impaired angiogenesis and a
decrease of chondroclast and osteoblast numbers in growth
plates (Dass et al., 2007). It has been suggested that VEGF-A is
involved not only in osteoclastic recruitment and
differentiation, but also in enhancing osteoclastic bone-
resorbing activity in cultured rabbit mature osteoclasts
(Nakagawa et al., 2000). A recent study demonstrated that
VEGF-A-elicited pathways are involved in the induction of
receptor of NF-B ligand (RANKL) expression, suggesting
that VEGF-A plays an important role in modulating the
angiogenic action of RANKL under physiological or
pathological conditions (Henriksen et al., 2003). In the process
of monocytic precursor cell differentiation, Niida et al. (1999)
demonstrated that VEGF-A can substitute for CSF-1 in the
presence of RANKL to promote osteoclastogenesis. Semi-
quantitative RT-PCR and fluorescence-activated cell-sorter
analysis revealed that VEGF-A can significantly increase both
mRNA expression and surface protein expression of receptor
activator of NF-B (RANK) in human endothelial cells,
thereby increasing the angiogenic responses of endothelial cells
to RANKL (Min et al., 2003). This up-regulation takes place
mainly through the Flk-1/KDR-PKC-ERK signaling pathway
(Min et al., 2003). VEGF-A can also up-regulate RANKL
expression in osteoclast precursors, but it cannot fully
substitute for CSF-1 to promote proliferation and
osteoclastogenesis (Yao et al., 2006). Furthermore, according
to a review by Zelzer and Olsen (2005), VEGF-A is produced
by hypertrophic chondrocytes, induces osteoclastogenesis in
the perichondrium, and stimulates migration of the osteoclasts
into hypertrophic cartilage through the extracellular signal-
regulated kinases 1 and 2 (ERK1/2) pathway (Henriksen et al.,
2003; Min et al., 2003).
VEGF-A Regulates Osteoblastic Activity
Although the exact mechanism of VEGF-A production and
secretion in osteoblasts has not yet been fully clarified, VEGFs
have been implicated in various aspects of osteoblast function.
In vitro, VEGF-A mRNA was found to be expressed in rat
calvaria-derived osteoblast-enriched cells (Harada et al., 1994).
During calvaria organ culture, treatment with VEGF-A
164
led to
Figure 4. Schematic representation of the role of VEGF and the
corresponding receptors on osteoblasts, chondrocytes, and
chondroclasts/osteoclasts. 
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a significant increase in the thickness of parietal bone,
demonstrating a stimulatory effect of VEGF-A on bone
formation (Zelzer et al., 2002). Several mechanisms for
controlling osteoblast activity have been proposed. First,
VEGF-A could couple angiogenesis and osteogenesis by
manipulating the angiogenic response to osteoblastic activity.
Second, VEGF-A could act as an autocrine regulator of
osteoblastic differentiation and activity. Third, by expressing
VEGF-A, osteoblasts could induce cells in the vicinity to
express factors that, in turn, regulate osteoblastic activity
(Zelzer and Olsen, 2005). The following studies support all
three possibilities.
In 24-day-old mice, the inhibition of VEGF-A by soluble
Flt-1 decreased angiogenesis, reduced cartilage formation, and
delayed cartilage resorption (Gerber et al., 1999). VEGF-A can
also directly promote differentiation of human primary cultured
osteoblasts (Street et al., 2002). Deckers et al. (2000) showed
that a low level of VEGF-A expression occurs at the early stage
of osteoblast differentiation, before the detection of mRNAs
encoding bone sialoprotein and osteocalcin. Only during the
terminal differentiation of osteoblasts is their expression greatly
increased, achieving a maximum level during the period of
mineralization (Deckers et al., 2000). This finding suggests that
VEGFs are indispensable in the regulation of bone remodeling,
because they stimulate osteoblast differentiation. Moreover, the
amount of increase in VEGF expression during
osteoblastogenesis depends on the maturity of the osteoblastic
cells (Furumatsu et al., 2003). Finally, VEGF-A acts as a
potent chemoattractant for rat and human osteoblasts, as well as
bone-marrow-derived mesenchymal progenitor cells
(Nakagawa et al., 2000; Mayr-Wohlfart et al., 2002; Fiedler et
al., 2005). VEGF treatment induces VEGF-D expression in
osteoblasts, and the inactivation of VEGF-D activity by
neutralizing antibodies or VEGFR-3 silencing inhibits both
VEGF-A- and VEGF-D-dependent nodule formation in
osteoblasts, suggesting that VEGF-D is a downstream effector
of VEGF-A in osteogenesis (Orlandini et al., 2006).
THERAPEUTIC IMPLICATIONS IN ENDOCHONDRAL
OSSIFICATION AND PERSPECTIVES
Several experiments with recombinant VEGF proteins or genes
have demonstrated that these treatment regimes seem to be
safe, and the results have been encouraging for the treatment of
coronary and limb ischemia (Street et al., 2002; Kastrup, 2003)
and burn wounds (Galeano et al., 2003). However, the VEGF-
A that was locally applied to rabbit tibia during distraction
osteogenesis increased the blood flow in the distracted limb,
but failed to influence bone mineral content and
histomorphometric indices of bone regeneration (Eckardt et al.,
2003). A possible explanation is that, during distraction
osteogenesis, a high level of endogenous VEGF-A has already
been secreted, and therefore the additional delivery of VEGF-A
has little or no effect, owing to optimal endogenous VEGF-A
signaling. Similar results were obtained in ex vivo gene therapy
based on retrovirus-transferred muscle-derived stem cells
(MDSCs): Supplying VEGF-A alone was not sufficient to
initiate the cascade of bone regeneration in the critical-sized
calvarial defects (Peng et al., 2002). However, VEGF-A acts
synergistically with BMP
4
to recruit mesenchymal stem cells
and induce cartilage formation and remodeling during
endochondral ossification (Peng et al., 2002).
Gain-of-function studies with recombinant VEGF-A
proteins or genes have increasingly found significant increases
Table 3. Effects of VEGF Protein and Gene Therapy on Endochondral Ossification
Growth 
Factor Delivery Method Animal Model Effects References
rhVEGF Microsphere injection Rabbit tibia distraction osteogenesis VEGF increased the blood flow in distracted bone, and Eckardt et al., 2003
VEGFR-2/Fc VEGF-inhibitor decreased bone blood flow, but failed to 
influence bone mineral content during bone regeneration
rhVEGF PLGA scaffolds Rat radiated calvarial defects Blood vessel formation, bone coverage, and Orlandini et al., 2006
bone mineral density were induced.
rhVEGF Bioactive glass Rat cranial bone defects Blood vessel density and bone mineral density were improved. Leach et al., 2006
rhVEGF Demineralized bone matrix Rabbit parietal bone defects New bone formation was enhanced. Rabie et al., 1996
rhVEGF Local injection Rat experimental tooth movement The number of osteoclasts during experimental tooth move- Kaku et al., 2001;
ment and the amount of tooth movement were improved. Kohno et al., 2003
rhVEGF Collagen type I carrier Rabbit mandibular defect More intensive angiogenesis and increased bone regeneration Kleinheinz et al., 2005
VEGF Gene-activated matrix Rabbit bone defects Vascularization and bone regeneration were improved. Geiger et al., 2005
VEGF Retrovirus transferred MDSCs* Mouse calvarial defects VEGF had a synergistic effect with BMP4 to recruit more Peng et al., 2002
BMP-4 mesenchymal stem cells, and to induce cartilage formation 
and remodeling during endochondral ossification.
VEGF-A Adenovirus local injection Rat femur defect Shortened endochondral phase and enhanced Tarkka et al., 2003
angiogenesis and osteogenesis
VEGF-A Adenovirus local injection Rabbit femur Stimulated osteoblast activity and more bone formation Hiltunen et al., 2003
VEGF164 AAV** local injection Rat mandibular condyle Increased size of mandibular condyle Rabie et al., 2007
RANKL
VEGF AAV-coated allografts Mouse femoral defect Increased bone remodeling and vascularization, which Ito et al., 2005
led to a new bone collar around the graft.
* MDSC, muscle-derived stem cells.
** AAV, adeno-associated virus.
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in vascularization and bone regeneration in defects (Table 3).
For example, when poly(lactic-co-glycolic acid) (PLGA)
scaffolds that have been incorporated with rhVEGF-A were
loaded into radiated calvarial defects of Fisher rats, there were
significant increases in blood vessel formation, bone coverage,
and bone mineral density when compared with defects loaded
with only PLGA scaffolds (Orlandini et al., 2006). Scaffolds
coated with a rhVEGF-A-releasing layer (bioactive glass) also
demonstrated significant improvements in blood vessel density
and bone mineral density in rat cranial bone defects (Leach et
al., 2006). The combination of rhVEGF-A and demineralized
bone matrix grafts (Rabie, 1997) significantly increased new
bone formation in rabbit parietal bone defects (Bassem et al.,
2006). Local administration of rhVEGF-A exhibited an
increased number of osteoclasts during experimental tooth
movement, as well as increases in the amount of tooth
movement (Kaku et al., 2001; Kohno et al., 2003). The use of
rhVEGF-A in bone defect models has shown that new blood
vessel formation preceded the osteogenic front, and that
increased angiogenesis corresponded to increased bone
formation (Kleinheinz et al., 2005). Although these findings are
promising, the possible applications of these growth factors are
limited by the need for repeated and expensive dosages, and by
their short biological half-life (Zhang et al., 2002).
Recent advances in molecular biology have given promise
for the development of novel approaches, and gene therapy for
the maximal stimulation of osteogenesis ultimately overcomes
conventional growth factor delivery limitations, which act as a
one-time bolus (Chen et al., 2002). Using a gene-activated
matrix (GAM) to deliver the VEGF-A gene, Geiger et al.
(2005) demonstrated a significant increase in vascularization
and bone regeneration in rabbit bone defects. In vivo gene
therapy with adenoviral VEGF-A has been proven to be able to
modify bone defect healing in the rat femur (Tarkka et al.,
2003). Similarly, using a rabbit model, Hiltunen et al. (2003)
concluded that VEGF-A gene transfer delivered by an
adenovirus vector resulted in increased bone formation by
stimulating osteoblast activity. However, a major disadvantage
of current adenoviral vectors is the induction of a significant
host immune response (Jiang et al., 2001). They are therefore
inappropriate for the treatment of non-fatal craniofacial
anomalies. Among the viral and non-viral vectors, the
recombinant adeno-associated virus (rAAV) vector is an
efficient and safe procedure to facilitate gene induction in the
skeletal system. Ito et al. (2005) established an unconventional
means of evaluating cortical bone healing with femoral
allografts coated with freeze-dried rAAV encoding RANKL
and VEGF-A, and identified a continuing active resorption of
the dead cortical bone with new bone formation. This approach
markedly altered allograft healing and generated a live,
vascularized, remodeling, bony union. Local injection of rAAV
mediated VEGF-A expression in the condylar cartilage,
demonstrating a significantly increased size of the mandibular
condyle (Rabie et al., 2007). Therefore, VEGF-A has possible
clinical applications for achieving both angiogenesis and bone
formation. Further proof-of-concept advances are needed to
bring this approach to fruition, and to stimulate maximum
osteogenesis.
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